Safety and efficacy evaluation of pertuzumab in patients with solid tumors

Chenjing Zhu, MD\textsuperscript{a}, Wenwu Ling, MD\textsuperscript{b}, Jing Zhang, MD\textsuperscript{b}, Hui Gao, MD\textsuperscript{b}, Kai Shen, MD\textsuperscript{a}, Xuelei Ma, MD\textsuperscript{a,∗}

Abstract

Background: The development of targeted therapies benefits patients with certain markers in the treatment of breast cancer. Pertuzumab is a novel humanized monoclonal antibody that blocks human epidermal growth factor receptor 2 (HER2) dimerization. The Food and Drug Administration has approved pertuzumab in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Methods: To assess the safety and efficacy profile of pertuzumab, we searched PubMed and Embase (articles from January 1966 to January 2015) using the keyword “pertuzumab”.

Results: Fourteen eligible studies were included in our final analysis. From the results of our analysis, diarrhea (56.9%, 95% confidence interval [CI] 49.6%–63.9%), nausea (94.0%, 95% CI 27.7%–40.8%), and rash (25.6%, 95% CI 20.8%–31.0%) were the most common adverse effects in pertuzumab alone and pertuzumab-based therapies. Based on randomized controlled clinical trials, diarrhea (odds ratio [OR] 2.310, 95% CI 1.818–2.939), rash (OR 1.848, 95% CI 1.094–3.122), and febrile neutropenia (OR 1.672, 95% CI 1.130–2.474) were of statistical significance, which meant that pertuzumab played a prominent role in the incidence of diarrhea. Meanwhile, pertuzumab showed its effective role in cancer control and lifetime prolongation.

Conclusion: In conclusion, considering that the common adverse effects for pertuzumab are gastrointestinal and skin toxicities, which are easier to handle than other toxicities, pertuzumab is a safe and effective drug for patients with solid tumors.

Abbreviations: CI = confidence interval, HER2 = human epidermal growth factor receptor 2, NSCLC = nonsmall cell lung cancer, OR = odds ratio, PFS = progression-free survival, RCT = randomized controlled trial.

Keywords: adverse effect, diarrhea, nausea, pertuzumab, rash

1. Introduction

Breast cancer is one of the most common cancer among women worldwide."[1,2] Each year, approximately 1.68 million women were diagnosed with breast cancer worldwide, and over 500,000 women died of the disease (about 1400 deaths per day)."[3] Breast cancer might be controlled but usually not cured when diagnosed in the metastatic setting. However, the revolution in the molecular biology gives rise to an improved understanding of this disease and more options for the treatment. Although the incidence of the disease is continuously high, the mortality rate is reducing."

The 5-year survival rate of breast cancer was around 89% according to the statistics in 2014."[4] Many new systematic therapies for advanced breast cancer have been available over the decades, especially for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The intracellular pathways of HER2 protooncogene (also known as “neu” or “c-erbB-2”) are important pathways related to cell growth, proliferation, differentiation, and death."[5] and the overexpression or amplification of HER2 often indicates higher rates of recurrence and mortality in breast cancer."[6] A total of 15% to 20% of all the breast cancers are estimated to overexpress HER2 receptor, and thus, these patient populations can benefit from HER2-targeted therapy."[7] Pertuzumab is a humanized, recombinant, immunoglobulin G monoclonal antibody that targets HER2."[8] Unlike trastuzumab, pertuzumab shows its novelty which can either homodimerize with another HER2 receptor or heterodimerize with a different receptor of the HER family to activate certain downstream signaling pathways through phosphorylation of the tyrosine kinases."[9] It acts on the extracellular portion of HER2 receptor and functions as a competitive inhibitor of HER2 dimerization, leading to different effects on cancers. In previous clinical trials, pertuzumab showed its efficacy in HER2-overexpressed breast cancer and other cancers, such as ovarian and prostate cancer. The Food and Drug Administration (FDA) has approved pertuzumab in...
combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapies or chemotherapy for metastatic diseases.\textsuperscript{[11]} The European Medicines Agency also recommended this combination for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.\textsuperscript{[7]}

Previous clinical trials have reported that this monoclonal antibody is effective in the therapies for cancer patients, but the adverse effects caused by pertuzumab or pertuzumab-based therapies should also be considered, such as gastrointestinal, skin, and hematopoietic toxicities. The adverse effects might differ in each clinical trial, and some might not be caused by pertuzumab. Thus, we conducted this meta-analysis to evaluate the safety and efficacy profile of this drug.

2. Methods

2.1. Data source

PubMed (articles from January 1966 to January 2015) was searched using the keyword “pertuzumab”. The search was limited to clinical trials published in English. In addition, we reviewed Embase (articles from January 2000 to January 2015) for “pertuzumab” to make sure no additional studies were missed. After screening the titles and/or abstracts, duplicates were removed, and for those articles with similar data and study designs, only the most complete and recent clinical trial was included in our analysis. Two authors independently selected studies and discrepancies were resolved by discussion with a third author. As this was a meta-analysis, no ethical approval was required.

2.2. Study selection

In all phase I clinical trials, pertuzumab was used in the range of 0.5 to 20 mg/kg to evaluate the dose-limiting toxicity and maximum tolerated dose. In phase II and III clinical trials, pertuzumab was studied in 2 different dosing schedules: 840 mg as a loading dose followed by 420 mg every 3 weeks and 1050 mg every 3 weeks. Trials that met the following criteria were selected for the final analysis: prospective phase I, II, and III clinical trials in cancer patients; participants were treated with pertuzumab; data were available regarding the survival outcomes and incidences of all-grade or grade ≥3 adverse effects. Studies using pertuzumab as a single agent or in combination with other drugs were both included in our analysis.

2.3. Clinical endpoints

Data of clinical end points extracted from the trials were low-grade (1–2), high-grade (3–5), and all-grade (1–5) adverse effects according to the National Cancer Institute Common Toxicity Criteria version 2 or Common Terminology Criteria for Adverse Effects version 3. Other extracted data included the first author’s name, year of publication, the study design, population information, dosing schedules of pertuzumab, type of cancers, and concurrent antineoplastic medications used with pertuzumab.

2.4. Statistical analysis

We performed the statistical analyses using the Comprehensive Meta-Analysis program (Biostat, Englewood, NJ) version 2. For each study, the proportion of patients with each adverse effect (both all-grade and grade ≥3) in the pertuzumab arm was calculated, and the 95% confidence interval (CI) was derived. For all the randomized controlled studies comparing pertuzumab with placebo, we calculated the odds ratio (OR) of each adverse effect mentioned in at least 2 studies to determine the role pertuzumab plays in each adverse effect. We also extracted median progression-free survival (PFS) from single-agent pertuzumab trials and hazard ratios (HRs) with 95% CI from control-arm studies to evaluate the efficacy of pertuzumab. P and P values were evaluated to test heterogeneity, and when I² > 50% and P < .1, a random-effects model was used in the analysis.

2.5. Risk of bias and quality assessment

To evaluate the risk of bias and quality of the studies, QUADAS-2 was used as a systematic review assessment method, which consisted of 4 key domains: patient selection, index test, reference standard, and flow and timing. Risk of bias was rated as high/low/unclear. The assessment was measured using Review Manager (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014, Copenhagen, Sweden). A sensitivity analysis was also performed with a Newcastle–Ottawa Scale. Studies that achieved 6 or more stars on the Newcastle–Ottawa Scale were considered of high quality.

3. Results

3.1. Searching results

The initial search identified 20 potentially relevant articles on pertuzumab. The search of Embase did not yield any additional results. Six studies were excluded because they did not provide enough data for specific adverse effects. Our selection process is shown in Fig. 1.

Characteristics of the 14 eligible studies included in our final analysis are presented in Table 1. These studies included 2 phase I\textsuperscript{[12,13]} trials, 11 phase II\textsuperscript{[14–23]} trials, and 1 phase III\textsuperscript{[24]} trial. Five phase II trials used pertuzumab as a single agent\textsuperscript{[14–18]} 3 phase II trials used pertuzumab in combination with at least 1 agent,\textsuperscript{[22,23,25]} and the remaining 3 phase II trials were randomized controlled trials (RCTs)\textsuperscript{[19–21]} The phase III trial was a randomized, placebo-controlled study.\textsuperscript{[24]}

3.2. Patients

A total of 2249 patients from 14 clinical trials were included in our analysis. Seven trials (n = 392) evaluated pertuzumab as monotherapy. Three trials (n = 353) used pertuzumab plus other agents. Four trials (n = 1504; pertuzumab: 853; control: 651) compared the effects of pertuzumab arm with the control arm. The 14 studies included breast cancer (6 articles), prostate cancer (2 articles), ovarian cancer (3 articles), nonsmall cell lung cancer (NSCLC) (1 article), and other kinds of solid tumors (2 articles).

3.3. Rates of adverse effects and subgroup analysis

We recorded and evaluated the adverse effects in all 14 trials. We also compared the adverse effects in different dose levels and different tumor types. RCTs were analyzed to determine the role of pertuzumab in main adverse effects. We found that diarrhea, nausea, and rash were the most common all-grade adverse effects. The rates ranged from 20.9% to 86.5% for diarrhea, 6.1% to 75.4% for nausea, and 5.7% to 37.1% for rash. Then, we calculated the overall rate and 95% CI for each adverse effect. The pooled rates for diarrhea, nausea, and rash were 56.9%
Figure 1. Search results and study selection for all the clinical trials included in our study.

Table 1: Characteristics of all the eligible clinical trials.

| First author | Year of publication | Phase | Number of patients | Treatment regimen | Indications |
|--------------|---------------------|-------|--------------------|-------------------|-------------|
| Agus         | 2005                | I     | 21                 | Pertuzumab        | N/A         |
| Yamamoto     | 2009                | I     | 18                 | Pertuzumab        | N/A         |
| Gordon       | 2006                | II    | 123 (61, 62)       | Pertuzumab        | N/A         |
| de Bono      | 2007                | II    | 68 (35, 33)        | Pertuzumab        | N/A         |
| Gianni       | 2010                | II    | 78 (41, 37)        | Pertuzumab        | N/A         |
| Makhija*     | 2010                | II    | 130 (65, 65)       | Gemcitabine + placebo/pertuzumab | N/A         |
| Kaye*        | 2013                | II    | 149 (74, 75)       | Chemotherapy + pertuzumab/trastuzumab | N/A         |
| Gianni*      | 2012                | II    | 417 (310, 107)     | Pertuzumab + trastuzumab + docetaxel | N/A         |
| Schneeweiss  | 2013                | II    | 223                | Pertuzumab + trastuzumab | N/A         |
| Baselga      | 2010                | II    | 66                 | Pertuzumab + trastuzumab  | N/A         |
| Baselga*     | 2012                | III   | 808 (404, 404)     | Trastuzumab + docetaxel + pertuzumab/placebo | N/A         |
| Miller       | 2014                | IIa   | 64                 | T-DM1 + pertuzumab | N/A         |

Note: HER2 = human epidermal growth factor receptor 2.
* Randomized controlled trials.
Subgroup analysis based on types of tumors including breast cancer, ovarian cancer, prostate cancer, and NSCLC was performed. For the 3 main adverse effects discussed above, we found that adverse rates were higher in breast cancer and ovarian cancer than in prostate cancer and NSCLC. The adverse rates in ovarian cancer tended to be the highest. In patients with breast cancer, regardless of the stages and surface markers, the rates of adverse effect were similar, and this was also the case in ovarian and prostate cancer. Among all types of cancers, hormone refractory prostate cancer was prone to have the lowest rate of the 3 adverse effects (Table 3).

3.4. Adverse events of pertuzumab in RCTs

We selected RCTs to determine the OR of each adverse effect mentioned in more than 2 studies. Among all the adverse effects, diarrhea (OR 2.310, 95% CI 1.818–2.936), rash (OR 1.848, 95% CI 1.094–3.122), and febrile neutropenia (OR 1.672, 95% CI 1.130–2.474) were of statistical significance, which meant pertuzumab played a prominent role in the incidence of diarrhea [26] (Fig. 3A and B, Table 4). In grade ≥3 adverse effects, the rate of febrile neutropenia in the experimental group was significantly higher than that in the control group (OR 1.585, 95% CI 1.045–2.403) (Fig. 4).

3.5. Survival outcomes of pertuzumab

The data of median PFS which is the time from the date of first dose of study medication to documented progressive disease or death at any time [23] for pertuzumab in different kinds of tumors are shown in Table 5. In single-arm trials with pertuzumab alone, median PFS for ovarian cancer was 1.65 (95% CI 1.5–2.725) and for small-cell lung cancer was 1.525 (95% CI 1.325–2.825). Median PFS did not differ between different doses administered in patients with prostate cancer (420mg: 1.433, 95% CI 0.767–2.7 vs 1050mg: 1.433, 95% CI 0.833–2.1). Similar results were also seen in breast cancer (420mg: 1.467, 95% CI 1.267–2.733 vs 1050mg: 1.433, 95% CI 1.3–2.833). In control-arm trials using combination therapies, gemcitabine + pertuzumab and trastuzumab + docetaxel + pertuzumab showed a prolonged PFS, whereas chemotherapy + pertuzumab indicated that the addition of pertuzumab to carboplatin-based chemotherapy did not substantially prolong PFS in unselected patients with platinum-sensitive ovarian cancer. [20] Pertuzumab might stabilize diseases and prolong the survival of cancer patients; however, large-scale studies are needed to confirm the results we have obtained so far.

3.6. Risk of bias and quality assessment

The risk of bias and quality assessments of the included studies are outlined in Fig. 5A and B. Overall, the quality of the studies was satisfactory. Thirteen of the 14 included studies got 6 scores or more in methodological assessment. One study [13] got a score of 5.

4. Discussion

The safety profile of pertuzumab showed that the most significant adverse effect was diarrhea, indicating the high rate of gastrointestinal toxicities due to the use of pertuzumab in clinical
settings. Other adverse effects did not have such a strong relationship with pertuzumab compared with diarrhea. Single-arm and control-arm trials showed a prolonged PFS of pertuzumab, which meant that this drug might possess the capability to stabilize diseases and prolong the survival of cancer patients.

Gastrointestinal toxicities might be related to the blockage of HER2 function on normal cells.[27] Previous studies have shown that the proper functions of gastrointestinal tracts relied on the expression of HER2 receptors in many vital structures,[28] such as epithelial cells and enteric nervous system neurons.[29] Pertuzumab might act on receptors of these normal cells and interfere with their functions, leading to gastrointestinal toxicities. No specific guidelines were available for dealing with gastrointestinal toxicities caused by HER2 antibody, but similar situations caused by other chemotherapies could give us some hints. Intravenous amifostine was recommended for the management of gastrointestinal toxicities caused by chemotherapies inhibiting epidermal growth factor receptor (EGFR) in NSCLC.[30] As EGFR pathway is related to anti-HER2 therapy[31] and diarrhea is actually a manifestation of mucositis,[32] this mucosa protector amifostine might be effective in treating the diarrhea caused by pertuzumab as well. Furthermore, probiotics containing lactobacillus species were advised when the malignancy existed in the pelvic cavity, either in chemotherapy or radiation therapy.[30] Therefore, we could use lactobacillus probiotics to treat patients with diarrhea caused by ovarian cancer if pertuzumab is approved for future ovarian cancer therapy.

Nausea, rash and severe neutropenia also occurred in patients with pertuzumab-based therapies. Nausea was mainly of grades.

Papulopustule was the most common in pertuzumab-related rash.[33] Drucker et al.[33] advised that regular moisturization and the twice-daily application of sun-block SPF 15 or higher would be helpful. We also reviewed some studies to find out the mechanism of the rash. The finding showed that pertuzumab could affect EGFR pathway as in the mechanism of diarrhea. Some studies showed that novel anticancer drugs could inhibit the EGFR-RAS-RAF-MEK and PI3 kinase-AKT-m-TOR pathways to cause skin rash.[34–36] Since EGFRs are highly expressed on keratinocytes, the inhibition of these pathways might be associated with keratinocyte stress and therefore rash occurs.[37] However, future studies are needed to explore a clearer mechanism of HER2 inhibitors.

### Table 3

The highest and lowest rates of 3 meaningful adverse effects and the pooled event rates in different kinds of tumor.

| Adverse effect | Highest rate and 95% CI | Lowest rate and 95% CI | Pooled event rate in ovarian cancer | Pooled event rate in breast cancer | Pooled event rate in prostate cancer and NSCLC |
|----------------|------------------------|------------------------|------------------------------------|-----------------------------------|-----------------------------------------------|
| Diarrhea       | HER2-negative metastatic breast cancer (0.865, 0.714–0.943) | NSCLC (0.596, 0.566–0.626) | 0.685 (0.615–0.748) | 0.209 (0.113–0.356) | 0.420 (0.261–0.598) |
| Nausea         | Ovarian cancer (0.754, 0.635–0.843) | Hormone refractory prostate cancer (0.512, 0.352–0.413) | 0.512 (0.274–0.744) | 0.615 (0.251–0.356) | 0.196 (0.102–0.344) |
| Rash           | Advanced ovarian cancer (0.371, 0.261–0.497) | Hormone refractory prostate cancer (0.358, 0.240–0.417) | 0.358 (0.290–0.429) | 0.182 (0.080–0.225) | 0.137 (0.057–0.202) |

CI = confidence interval. HER2 = human epidermal growth factor receptor 2. NSCLC = non small cell lung cancer.

### Table 4

Odds ratio and 95% CI of adverse effects using random or fixed model.

| Adverse effect | Odds ratio with 95% CI | Model |
|----------------|------------------------|-------|
| Neutropenia    | 0.970 (0.639–1.473)    | Random model |
| Rash           | 1.848 (1.094–3.122)    | Random model |
| Alopecia       | 0.999 (0.776, 1.287)   | Fix model |
| Ashtenia       | 0.868 (0.656, 1.150)   | Fix model |
| Diarrhea       | 2.310 (1.818, 2.936)   | Fix model |
| Fatigue        | 1.074 (0.840, 1.374)   | Fix model |
| Febrile neutropenia | 1.672 (1.130, 2.474) | Fix model |
| Nausea         | 1.050 (0.828, 1.332)   | Fix model |
| Thrombocytopenia | 1.326 (0.811, 2.170)  | Fix model |

CI = confidence interval.
Moreover, we tried to find out what were the related factors of these adverse effects. We took tumor types, dosages of pertuzumab and concurrent drugs into consideration. As is shown in Table 3, tumors in females like breast cancer and ovarian cancer have noticeable higher rates in all 3 adverse effects when compared with prostate cancer and NSCLC, but no significant difference was found in different subtypes of tumors. In addition, prostate cancer seemed to have less adverse effects, which might indicate that the adverse effects were related to the sex hormone or genders, but the reason was unclear. No difference between the rates in 2 different dosages of pertuzumab was found.

In June 2012, the FDA initially approved pertuzumab for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy. The approval was based on a randomized, double-blind, placebo-controlled phase III CLEOPATRA (clinical evaluation of pertuzumab and trastuzumab). The trial set 2 arms, 1 for trastuzumab, docetaxel plus pertuzumab, and the other for trastuzumab, docetaxel plus placebo. A total of 808 patients were randomly allocated (1:1) to receive either of the 2 arms. Results showed statistically significant improvement in PFS in the pertuzumab arm (HR 0.62, 95% CI 0.51–0.75, P < .001).

### Table 5

**Survival outcomes of pertuzumab.**

| Study            | Sample size | Tumor types          | Median PFS (95% CI), mo |
|------------------|-------------|----------------------|------------------------|
| Gordon (2006)    | 117         | Ovarian cancer       | Overall population: 1.65 (1.5–2.725) |
|                  | 55          |                      | Cohort 1 (420 mg): 1.9 (1.5–2.85) |
|                  | 62          |                      | Cohort 2 (1050 mg): 1.525 (1.475–2.85) |
| de Bono (2007)   | 46          | Prostate cancer      | Cohort 1 (420 mg): 1.433 (0.767–2.7) |
|                  |             |                      | Cohort 2 (1050 mg): 1.433 (0.833–2.1) |
| Herbst (2007)    | 43          | Small cell lung cancer | 1.525 (1.325–2.825) |
| Gianni (2010)    | 41          | Breast cancer        | Cohort 1 (420 mg): 1.467 (1.267–2.733) |
|                  | 37          |                      | Cohort 2 (1050 mg): 1.433 (1.3–2.833) |

| Study            | Pertuzumab arm                  | Control arm                  | HR (95% CI) | P    | Tumor types |
|------------------|--------------------------------|-----------------------------|-------------|------|-------------|
| Makhija (2010)   | Gemcitabine + pertuzumab, 2.9   | Gemcitabine + placebo, 2.6  | 0.66 (0.43–1.03) | 0.0708 | Ovarian     |
| Kaye (2013)      | Chemotherapy + pertuzumab, 8.525| Chemotherapy, 9.325         | 1.16 (0.79–1.71) | 0.4487 | Ovarian     |
| Baselga (2012)   | Trastuzumab + docetaxel + pertuzumab, 18.5 | Trastuzumab + docetaxel + placebo, 12.4 | 0.62 (0.51–0.75) | <0.001 | Breast     |

CI = confidence interval, HR = hazard ratio, PFS = progression-free survival.
RCT conducted in 417 locally advanced, in mab+docetaxel. The pathologic complete response rates were +tratuzumab+docetaxel, pertuzumab+tratuzumab, or pertuzumab+docetaxel arms, respectively (39.3% and 21.5% in the pertuzumab+tratuzumab+docetaxel and the tratuzumab+docetaxel arms, respectively (P = .0063). Moreover, a large phase III clinical trial showed that pertuzumab gave an increased PFS of 6.1 months and a significant reduction in the risk of progression or death after adding pertuzumab to 1 current standard of care like trastuzumab. This combination is also well tolerated and effective. The combination therapy might benefit patients and FDA’s approval has also embodied this point. However, we should pay more attention to the possible increase of toxicities in the combined therapies. The heterogeneity of included studies is an important factor influencing the validity of the evaluation. These studies were done on different tumor types, different therapies, and even different races. Because of these differences, we found that it was not easy to obtain an objective value of rates. Under this circumstance, we think our results of subgroup analyses are more meaningful than the overall evaluation. There are several limitations of our study. The incomplete data of survival outcomes in each article made it hard to draw a specific conclusion of the efficacy of pertuzumab. In addition, the limited number of large phase III trials on pertuzumab might lead to some deviations with the actual situation. Further, large scale phase III RCTs are still needed to confirm our results.

5. Conclusion

In conclusion, pertuzumab is a safe and relatively effective agent in the therapies for solid tumors, even though it may possess some gastrointestinal toxicities such as diarrhea and nausea. Considering that these toxicities are relatively easy to handle with some mucosa protection agents, its safety can be guaranteed in clinical settings. Pertuzumab-based therapies are promising, and the potency can be further evaluated with more data in the future.

References

[1] Donepudi MS, Kondapalli K, Amos SJ, et al. Breast cancer statistics and markers. J Cancer Res Ther 2014;10:506–11.
[2] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–85.
[3] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403.
[4] Maass N, Schut F, Fasching PA, et al. Breast cancer update 2014—focus on the patient and the tumour. Geburtshilfe Frauenheilkd 2015;75:170–82.
[5] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:29–50.
[6] Nagy P, Jenes A, Damjanovics S, et al. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 1999;5:253–71.
[7] Boxe-Perales H, Borregaard J, Jensen KB, et al. The European Medicines Agency review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2014;19:766–73.
[8] Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2078–99.
[9] Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55:717–27.
[10] Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 2013;19:5532–6.
[11] Blumenthal GM, Scher NS, Cortazar P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 2013;19:4911–6.
[12] Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2343–47.
[13] Yamamoto N, Yamada Y, Fujii Y, et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab,
Zhu et al. Medicine (2017) 96:20

[14] Gordon MS, Mattei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324–32.

[15] de Bono JS, Bellmunt J, Attard G, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007;25:257–62.

[16] Agus DB, Sweeney CJ, Morris MJ, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007;25:675–81.

[17] Herbst RS, Davies AM, Natale RB, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab in platinum-resistant ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324–32.

[18] Gianni L, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in chemotherapy-naive patients with hormone-refractory prostate cancer. Jpn J Clin Oncol 2007;25:257–62.

[19] Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-sensitive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010;28:1131–7.

[20] Kaye SB, Poole CJ, Danska-Bidzinska A, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol 2013;24:145–52.

[21] Gianni L, Piekowska T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25–32.

[22] Schneweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278–84.

[23] Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior pertuzumab therapy. J Clin Oncol 2010;28:1138–44.

[24] Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010;10:489–91.

[25] Miller KD, Dierckx R, Harbeck N, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol 2014;32:1437–44.

[26] Hayes DF, Tock B, Harris AL. Assessing the clinical impact of prognostic factors: when is “statistically significant” clinically useful? Breast Cancer Res Treat 1998;32:305–19.

[27] Keefe DM, Gibson RJ. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 2007;15:483–90.

[28] Warren CM, Landgraf R. Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal 2006;18:923–33.

[29] Crone SA, Negro A, Trumpp A, et al. Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron 2003;37:29–40.

[30] Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014;120:1453–61.

[31] Badache A, Goncalves A. The ErbB2 signaling network as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 2006;11:13–25.

[32] Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol 2007;19:323–7.

[33] Drucker AM, Wu S, Dang CT, et al. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat 2012;135:347–54.

[34] Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–6.

[35] Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicentre trial in patients with advanced cancer. Clin Cancer Res 2010;16:1613–23.

[36] Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:1809–19.

[37] Moreno Garcia V, Thavasu P, Blanco Codroso M, et al. Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. Br J Cancer 2012;107:1797–800.

[38] Amiri-Kordestani L, Wedam S, Zhang L, et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 2014;20:5359–64.

[39] Petrelli F, Barni S. A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin Breast Cancer 2013;13:81–7.